Therefore, the main aim of this study is to identify the role of T-cell immune checkpoint molecules, NK immune checkpoint markers and cytokines derived from exosomes of ICIs treated NSCLC patients as biomarkers of response to anti-PD-1/PD-L1 therapy. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.